Duncker Streett Co Inc Lowers stake in Henry Schein (HSIC)

Henry Schein (HSIC) : Duncker Streett Co Inc reduced its stake in Henry Schein by 10.31% during the most recent quarter end. The investment management company now holds a total of 21,097 shares of Henry Schein which is valued at $3,559,064 after selling 2,426 shares in Henry Schein , the firm said in a disclosure report filed with the SEC on Apr 25, 2016.Henry Schein makes up approximately 1.31% of Duncker Streett Co Inc’s portfolio.

Henry Schein opened for trading at $168.86 and hit $171.21 on the upside on Monday, eventually ending the session at $171, with a gain of 1.36% or 2.3 points. The heightened volatility saw the trading volume jump to 5,84,507 shares. Company has a market cap of $14,012 M.

Other Hedge Funds, Including , North Point Portfolio Managers Corpoh boosted its stake in HSIC in the latest quarter, The investment management firm added 718 additional shares and now holds a total of 114,990 shares of Henry Schein which is valued at $19,398,813. Henry Schein makes up approx 3.73% of North Point Portfolio Managers Corpoh’s portfolio. Legacy Private Trust added HSIC to its portfolio by purchasing 4,620 company shares during the most recent quarter which is valued at $789,235. Henry Schein makes up approx 0.12% of Legacy Private Trust’s portfolio.Acadian Asset Management boosted its stake in HSIC in the latest quarter, The investment management firm added 20,214 additional shares and now holds a total of 641,867 shares of Henry Schein which is valued at $109,104,553. Henry Schein makes up approx 0.55% of Acadian Asset Management’s portfolio.Capstone Asset Management Co reduced its stake in HSIC by selling 205 shares or 2.07% in the most recent quarter. The Hedge Fund company now holds 9,685 shares of HSIC which is valued at $1,646,256. Henry Schein makes up approx 0.05% of Capstone Asset Management Co’s portfolio.

On the company’s financial health, Henry Schein reported $1.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 10, 2016. Analyst had a consensus of $1.65. The company had revenue of $2850.91 million for the quarter, compared to analysts expectations of $2817.65 million. The company’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.

Many Wall Street Analysts have commented on Henry Schein. Henry Schein was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016. Barrington Research Upgraded Henry Schein on Mar 1, 2016 to ” Outperform”, Price Target of the shares are set at $182.Company shares were Reiterated by Piper Jaffray on Feb 11, 2016 to “Neutral”, Firm has raised the Price Target to $ 159 from a previous price target of $158 .

Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.

Leave a Reply

Henry Schein - Is it time to Sell?

Top Brokerage Firms are advising their investors on Henry Schein. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.